EP08.02-014 Impact of East Asian Ancestry on Response to First-Line Osimertinib: A Real-World Canadian Cohort

Abstract

The phase-III FLAURA clinical trial demonstrated benefit and effectiveness of osimertinib as a first-line treatment for EGFR-mutant NSCLC patients; however, subgroup analysis suggests the magnitude of benefit may differ between Asian and non-Asian patients. Prior real-world data from our institution also suggests EGFR-mutant NSCLC patients of Asian racial ancestry are the most likely to derive benefit from earlier generation EGFR-inhibitors. This study examined real-world clinical population of EGFR-mutant patients treated with first-line osimertinib to compare and contrast the characteristics and response to osimertinib among Asian and non-Asian patients.